{"prompt": "['MK-7902', 'PAGE 14', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'of new anticancer therapy). The second sensitivity analysis considers discontinuation of', 'treatment or initiation of an anticancer treatment subsequent to discontinuation of study-specified', 'treatments, whichever occurs later, to be a PD event for participants without documented PD or', 'death. If a participant meets multiple criteria for censoring, the censoring criterion that occurs', 'earliest will be applied. The censoring rules for primary and sensitivity analyses are summarized', 'in Table 2.', 'Table 2 Censoring Rules for Primary and Sensitivity Analyses of Progression-free Survival', 'Situation', 'Sensitivity', 'Sensitivity', 'Primary Analysis', 'Analysis 1', 'Analysis 2', 'No PD and no death; new', 'Censored at last disease', 'Censored at last', 'Progressed at treatment', 'anticancer treatment is not', 'assessment', 'disease assessment', 'discontinuation for reasons', 'initiated', 'other than CR; otherwise,', 'censored at last disease', 'assessment if still on study', 'intervention or completed', 'study intervention', 'No PD and no death; new', 'Censored at last disease', 'Censored at last', 'Progressed at date of new', 'anticancer treatment is', 'assessment before new', 'disease assessment', 'anticancer treatment', 'initiated', 'anticancer treatment', 'PD or death documented', 'Progressed at date of', 'Progressed at date of', 'Progressed at date of', 'after 1 missed disease', 'documented PD or death', 'documented PD or', 'documented PD or death', 'assessment and before new', 'death', 'anticancer therapy', 'PD or death documented', 'Censored at last disease', 'Progressed at date of', 'Progressed at date of', 'immediately after >2', 'assessment before the', 'documented PD or', 'documented PD or death', 'consecutive missed disease', 'earlier date of', 'death', 'assessments or after new', '>2 consecutive missed', 'anticancer therapy', 'disease assessment and', 'new anticancer therapy', 'Abbreviation: CR = complete response; PD = progressive disease.', 'In case the proportional hazards assumption is not valid, Restricted Mean Survival Time (RMST)', 'method may be conducted for PFS to account for the possible non-proportional hazards effect as', 'a sensitivity analysis.', '3.6.1.2.', 'Overall Survival', 'The nonparametric Kaplan-Meier method will be used to estimate the survival curves. The', 'treatment difference in survival will be assessed by the stratified log-rank test (based on the', 'stratification factors defined in Section 6.3.2 in the protocol). A stratified Cox proportional', \"hazard model with Efron's method of tie handling will be used to assess the magnitude of the\", 'treatment difference (ie, the HR). The HR and its 95% CI from the stratified Cox model with a', 'single treatment covariate will be reported. The stratification factors used for randomization', '(Section 6.3.2 in the protocol) will be applied to both the stratified log-rank test and the stratified', 'Confidential']['MK-7902', 'PAGE 15', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Cox model. Participants without documented death at the time of analysis will be censored at the', 'date of last known contact.', 'In case the proportional hazards assumption is not valid, RMST method may be conducted for', 'OS to account for the possible non-proportional hazards effect as a sensitivity analysis.', '3.6.1.3.', 'Objective Response Rate', 'The stratified Miettinen and Nurminen method will be used for comparison of ORR between the', 'treatment groups. The difference in ORR and its 95% CI from the stratified Miettinen and', 'Nurminen method with strata weighting by sample size will be provided. The same stratification', 'factors used for randomization (Section 6.3.2 in the protocol) will be used as stratification factors', 'in the analysis.', '3.6.1.4.', 'Duration of Response', 'For subjects who demonstrate CR or PR, DOR is defined as the time from first documented', 'evidence of CR or PR until PD or death due to any cause, whichever occurs first.', 'The nonparametric Kaplan-Meier method will be used to summarize the DOR. The median and', 'range of DOR will be provided.', 'Censoring rules for DOR are summarized in Table 3.', 'Table 3 Censoring Rules for Duration of Response', 'Situation', 'Date of Progression or Censoring', 'Outcome', 'No PD or death, no new anticancer', 'Censor', 'Last adequate disease assessment', 'therapy initiated', '(nonevent)', 'No PD or death, new anticancer', 'Last adequate disease assessment before new', 'Censor', 'therapy initiated', 'anticancer therapy initiated', '(nonevent)', 'Death or PD immediately after >2', 'consecutive missed disease', 'Earlier date of last adequate disease assessment', 'Censor', 'assessments or after new anticancer', 'before >2 missed adequate disease assessments', '(nonevent)', 'and new anticancer therapy, if any', 'therapy, if any', 'Death or PD after 1 missed disease', 'End of response', 'assessments and before new anticancer', 'PD or death', '(event)', 'therapy, if any', 'Abbreviation: PD = progressive disease.', 'Note: A missed disease assessment includes any assessment that is not obtained or is considered inadequate for', 'evaluation of response.', '3.6.2.', 'Statistical Methods for Safety Analyses', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs, laboratory tests, vital signs, and ECG measurements.', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}